Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TOP1288 in Healthy Volunteers
NCT03071081Phase 1Completed
- Sponsor
- TopiVert Pharma Limited
- Start
- Feb 2017
- Primary completion
- Jun 2017
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TOP-1288 in ulcerative colitis (UC) (6 arms), sponsored by TopiVert Pharma Limited. Primary endpoints: Safety (AEs), Safety (ECGs) and 2 more. Started Feb 2017; status: completed.
02
Drugs
TOP-1288
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03071081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03071081.